Ola Lindén
1 – 10 of 38
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2013
-
Mark
90Yttrium-Ibritumomab-Tiuxetan as First-Line Treatment for Follicular Lymphoma: 30 Months of Follow-Up Data From an International Multicenter Phase II Clinical Trial.
(
- Contribution to journal › Article
- 2011
-
Mark
Dosimetry in patients with B-cell lymphoma treated with [90Y]ibritumomab tiuxetan or [131I]tositumomab.
(
- Contribution to journal › Article
-
Mark
T Cells in Tumors and Blood Predict Outcome in Follicular Lymphoma Treated with Rituximab
(
- Contribution to journal › Article
-
Mark
Inhibition of geranylgeranylation mediates sensitivity to CHOP-induced cell death of DLBCL cell lines.
(
- Contribution to journal › Article
- 2010
-
Mark
Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma
(
- Contribution to journal › Article
-
Mark
90Y Bremsstrahlung Imaging for Absorbed-Dose Assessment in High-Dose Radioimmunotherapy.
(
- Contribution to journal › Article
-
Mark
Diversity in antibody-based approaches to non-Hodgkin lymphoma
(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
-
Mark
EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry
(
- Contribution to journal › Article
-
Mark
90Yttrium Ibritumomab Tiuxetan as First Line Treatment for Follicular Lymphoma First Results from an International Phase II Clinical Trial
(
- Contribution to journal › Published meeting abstract
-
Mark
Extracorporeal techniques for improving radioimmunotherapy of disseminated malignant tumors
2010)(
- Chapter in Book/Report/Conference proceeding › Book chapter